Sunovion To Purchase Elevation And Phase II Drug/Device Combo For COPD
This article was originally published in PharmAsia News
Earlier than anticipated exit for Elevation means less dilution for its venture capital backers, who had provided $30 million in Series B funds this past January.
You may also be interested in...
The two-tranche financing, backed 50% by new investor Novo Ventures, will enable the private firm to evaluate early partnering opportunities from a position of financial stability.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.